The stock of X4 Pharmaceuticals Inc (NASDAQ:XFOR) last traded at $0.74, down -5.13% from the previous session.
Data from the available sources indicates that X4 Pharmaceuticals Inc (NASDAQ:XFOR) is covered by 8 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $2.60, we find $3.00. Given the previous closing price of $0.78, this indicates a potential upside of 284.62 percent. XFOR stock price is now -14.18% away from the 50-day moving average and -43.64% away from the 200-day moving average. The market capitalization of the company currently stands at $123.79M.
In total, 0 analysts have assigned it a hold rating, and 8 have given it a buy rating. Brokers who have rated the stock have averaged $3.45 as their price target over the next twelve months.
In other news, Ragan Paula, President and CEO sold 39,906 shares of the company’s stock on Nov 03. The stock was sold for $35,915 at an average price of $0.90. Upon completion of the transaction, the President and CEO now directly owns 836,441 shares in the company, valued at $0.62 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 01, Chief Financial Officer Mostafa Adam S. sold 230,645 shares of the business’s stock. A total of $168,371 was realized by selling the stock at an average price of $0.73. This leaves the insider owning 80,221 shares of the company worth $59363.54. A total of 24.68% of the company’s stock is owned by insiders.
With an opening price of $0.7600 on Friday morning, X4 Pharmaceuticals Inc (NASDAQ: XFOR) set off the trading day. During the past 12 months, X4 Pharmaceuticals Inc has had a low of $0.65 and a high of $2.58. As of last week, the company has a debt-to-equity ratio of 0.86, a current ratio of 5.81, and a quick ratio of 5.81. The fifty day moving average price for XFOR is $0.8561 and a two-hundred day moving average price translates $1.3117 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc (NASDAQ: XFOR) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.15 by 0.14. This compares to -$0.26 EPS in the same period last year. The company reported revenue of $27.21 million for the quarter, compared to $20.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.03 percent.
